Some experience with another company, ZLD. They have a CBD based formulation for insomnia currently available under SAS for over 12 months. Unfortunately the uptake (and attached revenue) has been fairly limited as many GPs are still very hesitant to prescribe CBD / THC. Either that or they're unaware of the drug's potential benefits (still).
Check Zelira's annual for revenue data.
- Forums
- ASX - By Stock
- IHL
- General discussion
General discussion, page-7639
-
- There are more pages in this discussion • 12,772 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)